Screener
Immunovant, Inc. IMVT Ratios & Valuation
| Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -64.8%-2.4pp | -69.3%+4.8pp | -95.9%-3.8pp | -77.6%-13.0pp | -62.5%-9.5pp | |
| Liquidity | ||||||
| Current ratio | 9.1×-2.1× | 15.7×+9.7× | 9.1×+1.5× | 12.3×-0.8× | 11.2×-2.5× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | —— | —— | —— | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $4.67+0.1% | $5.43+126% | $2.99-2.4% | $3.56-4.5% | $4.67+4.3% | |
| Valuation | ||||||
| Market capitalization | $8.11B+197% | $5.12B+40.9% | $2.81B-32.5% | $2.73B-28.7% | $2.9B-37.8% | |
| Price / book | 9.5×+5.0× | 5.2×-5.1× | 5.4×-3.9× | 4.5×-2.6× | 4.1×-3.5× |
FAQ
- Where do Immunovant, Inc.'s ratios come from?
- Every ratio is computed from Immunovant, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.